



NEWS RELEASE

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

2026-01-21

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- **Artiva Biotherapeutics, Inc.** (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL).

The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings:

Poster ID: 440	AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases
Poster Session:	Health Services and Barriers to Access
Date / Time:	Thursday, February 5, 2026, at 6:30 pm MST
Author:	Nicholas Veomett, Ph.D., Vice President, Corporate Development, Artiva Biotherapeutics
Poster ID: 511	A Multi-Center, Phase 1/2 Trial of AlloNK® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non-Hodgkin

Poster Session: Lymphoma
Date / Time: Lymphoma – Clinical
Thursday, February 5, 2026, at 6:30 pm MST
Author: Umer Farooq, M.D., Clinical Professor of Internal Medicine-Hematology, Oncology and Blood & Marrow Transplantation,
University of Iowa

For more information on these abstracts, visit the **2026 Tandem Meetings** website.

About Artiva Biotherapeutics

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva's lead program, AlloNK[®] (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren's disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva's pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell's NK cell manufacturing technology and programs.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (the "Tandem Meetings"), Artiva Biotherapeutics, Inc.'s (the "Company") participation at the Tandem Meetings, and the Company's mission, product candidates (including their potential to be cost effective, administrability in a community rheumatology practice, and durability), clinical trials, pipeline, and strategic partnerships. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company's actual results to differ from current expectations are discussed in the Company's filings with the Securities and Exchange Commission (the "SEC"), including the section titled "Risk Factors" in the Company's

Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Investors

Noopur Batsha Liffick, MPH

NBL LifeSci Advisory LLC

ir@artivabio.com

Media

Jessica Yingling, Ph.D.

Little Dog Communications Inc.

jessica@litldog.com

Source: Artiva Biotherapeutics, Inc.

Source: Artiva Biotherapeutics, Inc.